COSMOS Pharmaceutical (3349) Q2 2026 earnings summary

Executive summary

• Net sales for the six months ended November 30, 2025, rose 6.2% year-over-year to ¥537,175 million, with operating profit up 1.6% to ¥20,676 million and profit attributable to owners of parent up 1.5% to ¥14,648 million.

• 33 new stores were opened across multiple regions, bringing the total to 1,640, despite a sluggish Japanese economy and weak consumer sentiment.

Financial highlights

• EBITDA increased 4.6% year-over-year to ¥31,481 million.

• Gross profit rose to ¥112,882 million from ¥106,074 million a year earlier.

• Comprehensive income reached ¥14,640 million, up 1.5% year-over-year.

• Basic earnings per share were ¥184.83, reflecting a 2-for-1 stock split.

Outlook and guidance

• Full-year net sales forecast is ¥1,057,000 million, up 4.5% year-over-year, with operating profit expected at ¥40,500 million and profit attributable to owners of parent at ¥31,000 million.

• No changes to the previously announced financial results forecast.